Statute Details
- Title: Medicines (Licensing, Standard Provisions and Fees) Regulations
- Act Code: MA1975-RG6
- Legislation Type: Subsidiary legislation (SL)
- Authorising Act: Medicines Act (Cap. 176), Section 74
- Citation: Medicines (Licensing, Standard Provisions and Fees) Regulations (Rg 6)
- Gazette / Original Citation: G.N. No. S 174/1987
- Current Status: Current version as at 27 Mar 2026
- Key Provisions (from extract): Sections 2–6 (including standard provisions, grant of licences, fees, evaluation costs, and offences)
- Schedules: First Schedule (product licence); Second Schedule (import licence); Third Schedule (wholesale dealer’s licence); Fourth Schedule (manufacturer’s licence); Fifth Schedule (fees); Sixth Schedule (repealed)
What Is This Legislation About?
The Medicines (Licensing, Standard Provisions and Fees) Regulations (“the Regulations”) sit alongside the Medicines Act to create the practical licensing framework for regulated medicinal products in Singapore. In plain terms, the Regulations tell applicants and licence holders what they must do to obtain and maintain licences for products, imports, wholesale dealing, and manufacturing. They also set out the standard conditions that automatically attach to those licences, and they prescribe the fees payable for applications and related processes.
While the Medicines Act establishes the overall licensing regime, the Regulations operationalise it. They do so by (i) defining key terms used in the licensing context, (ii) specifying “standard provisions” for each licence type via schedules, (iii) governing how licences are granted and what must be included, (iv) setting fees, and (v) creating an offences framework for contraventions of licence standard provisions. The result is a compliance-heavy regime: licence holders are expected not merely to hold a licence, but to adhere to detailed operational and documentary requirements.
A notable feature of the Regulations is that they include tailored standard provisions for Chinese proprietary medicines. These provisions include additional documentary submissions and microbiological/chemical testing requirements after import, as well as approval and validity conditions for dealing with products under the licence. This reflects a risk-based approach to product categories and regulatory confidence in quality and safety.
What Are the Key Provisions?
1) Definitions and regulatory vocabulary (Section 2)
Section 2 provides definitions that matter for licensing and compliance. For example, it defines the “licensing authority” as the Chief Executive of the Authority (in practice, the Health Sciences Authority context), and it defines regulatory concepts such as “major variation” (changes to product specifications relating to indications, dosage recommendations, patient groups, or clinical trial information). It also defines “competent drug regulatory agency” and “reference drug regulatory agency” for international regulatory reference purposes, and it defines “psychotropic substance” by reference to another set of regulations.
2) Standard provisions for licences (Section 3)
Section 3 is the core mechanism. It provides that, subject to limited exceptions, the standard provisions for licences granted under Part II of the Medicines Act are those set out in the relevant schedules: First Schedule for product licences, Second Schedule for import licences, Third Schedule for wholesale dealer’s licences, and Fourth Schedule for manufacturer’s licences.
Importantly, Section 3 also contains special rules for Chinese proprietary medicines. Under Section 3(2), the standard provisions for import licences for Chinese proprietary medicines largely follow the Second Schedule but with specified modifications. These include: (a) excluding certain paragraphs of the Second Schedule; (b) requiring the licence holder to seek prior approval from the licensing authority to deal with any medicinal product under the licence, and to provide information and documents within a time specified by the authority; and (c) restricting dealing with products to situations where the approval remains valid and where the holder complies with all applicable written law.
Section 3(2) further imposes a post-import submission obligation for Chinese proprietary medicines: the licence holder must not sell or supply the medicinal product unless and until specified documents and test results are submitted to the licensing authority within two months of the import of the consignment. The extract shows that these include declarations regarding the absence of poison (as defined in the Poisons Act) and synthetic active substances, test results on specified substances under the Medicines (Prohibition of Sale and Supply) Order, and microbiological testing depending on whether the product is for oral consumption or external application. The microbiological lists include organisms such as Escherichia coli, Salmonella, Staphylococcus aureus, and counts for total yeast and mould and total aerobic microbial count; for external application, Pseudomonas aeruginosa is also specified.
3) Grant of licences (Section 4)
Section 4 governs the grant of licences and indicates that every product licence, wholesale dealer’s licence, and manufacturer’s licence granted shall be subject to the standard provisions. Practitioners should treat this as a “conditions attach” rule: even where the licence document itself may not restate every condition, the standard provisions in the schedules operate as binding requirements. This is crucial for enforcement and for advising clients on compliance scope.
4) Fees and evaluation costs (Sections 5 and 5A)
Section 5 provides that fees apply to applications for, and the grant of, licences and certificates, and for certain other regulatory processes (the extract indicates “and for a …” suggesting additional fee categories). Section 5A addresses the cost of evaluation, which is particularly relevant where the authority undertakes an assessment beyond routine processing. For legal and regulatory teams, fee provisions matter because they can affect timelines, budgeting, and the procedural steps required before a licence can be granted or maintained.
5) Offences and contraventions (Section 6)
Section 6 creates an offences framework for holders who contravene or fail to comply with any standard provision applicable to them. Even though the extract truncates the remainder of the text, the practical takeaway is clear: standard provisions are not merely administrative guidance; they are enforceable obligations. For counsel, the key is to map the client’s licence type to the relevant schedule and then to identify which standard provisions are most likely to be breached in real-world operations (e.g., approvals, documentation submissions, and restrictions on dealing with products).
How Is This Legislation Structured?
The Regulations are structured around a short set of operative sections and multiple schedules that contain the substantive “standard provisions” and the fee schedule.
Sections: The Regulations begin with a citation and definitions (Section 1 and Section 2). Section 3 sets out standard provisions by reference to schedules and includes special modifications for Chinese proprietary medicines. Section 4 addresses the grant of licences. Sections 5 and 5A deal with fees and evaluation costs. Section 6 addresses offences for contraventions.
Schedules: The schedules are where most compliance content lives. The First Schedule contains standard provisions for product licences; the Second Schedule for import licences; the Third Schedule for wholesale dealer’s licences; and the Fourth Schedule for manufacturer’s licences. The Fifth Schedule sets out the fees. The Sixth Schedule is repealed, indicating that some historical fee or transitional provisions have been removed.
From a practitioner’s perspective, the schedules are the “work product” of the Regulations: they translate licensing policy into operational requirements. When advising clients, lawyers should always cross-reference the licence category and product category (including whether the product is a Chinese proprietary medicine) to the correct schedule and any schedule modifications.
Who Does This Legislation Apply To?
The Regulations apply to persons and entities seeking or holding licences under Part II of the Medicines Act. This includes: (i) product licence holders, (ii) import licence holders, (iii) wholesale dealers, and (iv) manufacturers. The licensing authority is the Chief Executive of the relevant authority, and the standard provisions are designed to be binding on licence holders.
In addition, the Regulations apply differently depending on the product category. The extract shows that Chinese proprietary medicines are subject to modified standard provisions for import licences, and corresponding modifications for wholesale dealer’s and manufacturer’s licences. Accordingly, a business that deals in Chinese proprietary medicines must expect additional approval steps and post-import documentation and testing obligations before selling or supplying.
Why Is This Legislation Important?
This Regulations is important because it operationalises compliance. In Singapore’s medicines regulatory environment, licensing is not a one-time administrative step; it is a continuing permission conditioned on adherence to standard provisions. Section 3’s schedule-based approach means that the compliance obligations are embedded in the regulatory architecture and can be enforced even if a licence holder focuses only on the licence document’s express terms.
For practitioners, the Regulations are also significant because they create concrete compliance triggers and timelines. The two-month submission window for certain test results for Chinese proprietary medicines is a clear example of a time-bound obligation that can affect supply chain operations, release of stock, and contractual arrangements with distributors and retailers. Failure to comply can expose the licence holder to offences under Section 6 and can also lead to regulatory action affecting market access.
Finally, the fee and evaluation cost provisions matter for transaction planning. Licensing and evaluation processes can be expensive and may involve additional costs where the authority evaluates applications. Lawyers advising on mergers, acquisitions, or distribution agreements involving licensed entities should consider how fees and evaluation costs may affect closing conditions, ongoing compliance budgets, and the risk profile of regulatory delays.
Related Legislation
- Medicines Act (Cap. 176), including Part II licensing framework and Section 74 (authorising provision)
- Poison Act (Cap. 234) (referred to for “absence of any poison” declarations)
- Medicines (Prohibition of Sale and Supply) Order (O 4) (referred to for specified substance testing)
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (O 6) (referred to for definition of “Chinese proprietary medicine”)
- Medicines (Export Licence for Psychotropic Substances) Regulations (Rg 9) (referred to for definition of “psychotropic substance”)
Source Documents
This article provides an overview of the Medicines (Licensing, Standard Provisions and Fees) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.